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Abstract
Background: Parkinson’s disease (PD) is characterized by dopaminergic neurodegeneration in the substantia nigra
(SN). Transforming growth factor-b1 (TGF-b1) levels increase in patients with PD, although the effects of this
increment remain unclear. We have examined the mesostriatal system in adult mice deficient in Smad3, a molecule
involved in the intracellular TGF-b1 signalling cascade.
Results: Striatal monoamine oxidase (MAO)-mediated dopamine (DA) catabolism to 3,4-dihydroxyphenylacetic acid
(DOPAC) is strongly increased, promoting oxidative stress that is reflected by an increase in glutathione levels.
Fewer astrocytes are detected in the ventral midbrain (VM) and striatal matrix, suggesting decreased trophic
support to dopaminergic neurons. The SN of these mice has dopaminergic neuronal degeneration in its rostral
portion, and the pro-survival Erk1/2 signalling is diminished in nigra dopaminergic neurons, not associated with
alterations to p-JNK or p-p38. Furthermore, inclusions of a-synuclein are evident in selected brain areas, both in the
perikaryon (SN and paralemniscal nucleus) or neurites (motor and cingulate cortices, striatum and spinal cord).
Interestingly, these a-synuclein deposits are detected with ubiquitin and P
S129-a-synuclein in a core/halo cellular
distribution, which resemble those observed in human Lewy bodies (LB).
Conclusions: Smad3 deficiency promotes strong catabolism of DA in the striatum (ST), decrease trophic and
astrocytic support to dopaminergic neurons and may induce a-synuclein aggregation, which may be related to
early parkinsonism. These data underline a role for Smad3 in a-synuclein and DA homeostasis, and suggest that
modulatory molecules of this signalling pathway should be evaluated as possible neuroprotective agents.
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Background
PD is characterized by the progressive degeneration
of dopaminergic neurons in the SN pars compacta. These
neurons project to the ST and secrete DA in order
to control voluntary movements and rewarding events [1].
Another significant feature of PD is the presence of cyto-
plasmic and neuritic inclusions of a-synuclein, known
as LB and neurites. The aetiology of idiopathic PD is
unknown, although current hypotheses focus on increased
oxidative stress, aberrant protein folding, defective protea-
some degradation or mitochondrial dysfunction. Given this
diversity in the underlying molecular mechanisms, it has
been suggested that multiple factors may cause the disease
[2]. However, the central mechanisms that induce dopami-
nergic neuron loss and a-synuclein aggregation remain
unclear.
TGF-b1 is a cytokine that might mediate some molecu-
lar mechanisms of the disease. This molecule is expressed
at low levels in uninjured brains, while it is up-regulated
in the brain in association with diseases such as Parkin-
son’s and Alzheimer’s disease, Down syndrome, ischemic
lesion, hydrocephalus or spinal cord injury [3-10].
TGF-b1 is a highly pleiotropic molecule that can regu-
late cell proliferation, migration, differentiation and apop-
tosis. Its effect is cell type and context-dependent, and it
may provide signals for both cell survival and apoptosis
[11]. Moreover, a role for TGF-b in neuronal plasticity is
becoming evident. In Drosophila, the maintenance and
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requires TGF-b-mediated transcriptional regulation
[12,13]. In Aplysia, TGF-b1 induces long-term facilitation
in sensory-motor synapses [14].
During mammalian embryonic development, TGF-b3
(but not TGF-b1) is necessary for the survival of midbrain
dopaminergic neurons at perinatal stages [15]. Hence,
while TGF-b3 appears to exert its effects on newborns
neurons, TGF-b1 might have pathological effects in adults.
The context-dependent effects of these factors are clearly
observed in sensory neurons, where ontogenic neuronal
death is increased by TGF-b [16]. In the nigrostriatal sys-
tem of MPTP-treated mice, adenoviral overexpression of
active TGF-b1 produces a decrease in the survival of dopa-
minergic neurons, accompanied by higher levels of striatal
DA depletion [17,18]. Despite these studies, the role of
TGF-b in the adult mesostriatal system is not well
characterized.
The TGF-b subfamily of cytokines exert their effect by
binding to heteromeric receptor complexes at the cell sur-
face that contain a type I (primarily ALK5, but also ALK2
o rA L K 1 )a n dat y p eI Ir e c e p t o r( T bR-II or ActR-IIB).
Ligand binding to the receptor complex promotes the
recruitment and phosphorylation of Smad3 and/or Smad2.
Activated Smad3/2 interacts with Smad4 inducing their
translocation to the nucleus, where they bind to DNA
through specific Smad-binding elements, thereby promot-
ing targeted gene transcription. Some of the ligands that
can activate Smad3 and/or Smad2 are TGF-b1, -b2, -b3,
Inhibin, Activin, Nodal, GDF1, Vg1, and Lefty. This cano-
nical TGF-b pathway can cross-talk at multiple levels with
other signalling pathways such as those mediated by
MAPK, Fas, CaMKII, PKC, etc [11].
To address the role of TGF-b in the adult nigrostriatal
system, we have analyzed Smad3 null mice. We provide
evidence that Smad3 deficiency diminishes the trophic
and astrocytic support to nigral dopaminergic neurons, as
well as strongly altering DA metabolism. In addition a-
synuclein over-expression is produced in these mice, with
the formation of aggregates in different telencephalic,
mesencephalic and romboencephalic regions.
Results
Smad3 is expressed in dopaminergic neurons of the SN
To determine whether molecules related to TGF-b sig-
nalling are expressed in the adult murine nigrostriatal
system, we examined the expression of mRNA transcripts
encoding: TGF-b1, -b2a n d- b3 ligands; type I receptors
ALK1, ALK2 and ALK5; the type II receptor TbR-II; the
Smad signalling molecules Smad2, Smad3, Smad4; and
the inhibitor Smad7. RT-PCR analysis showed that all
these molecules are expressed in the VM and ST of adult
mice, with the exception of TGF-b3 and AKL1 in the
V M( F i g u r e1 A ) .T h ea b s e n c eo fT G F - b3 expression in
the VM suggests that this molecule is not critical for
Smad3 signalling in adults, in contrast with perinatal
stages [15]. We further assessed whether TGF-b signal-
ling might be present in dopaminergic neurons by histo-
logical analysis of Smad3 on tyrosine hydroxylase (TH)
positive neurons. Dopaminergic neurons in the SN
express Smad3, primarily in the cytoplasm, although
some neurons with nuclear localization were also
detected (Figure 1B, 2F, arrows). We also observed a
population of TH
+/Smad3
- and Smad3
+/TH
- cells in the
SN. The presence of Smad3 in TH-ir cells indicates that
TGF-b ligands can act directly on dopaminergic neurons.
We further assessed Smad3 expression in other brain
areas related to parkinsonism, such as the ST and the
motor cortex. Confocal analysis suggested that Smad3
was present in the nucleus of cells of the striatal matrix
compartment (the TH-fibre rich region). On the other
hand, TH-fibre innervation was detected throughout the
motor cortex, with Smad3 mainly expressed in the
nucleus of cells of the third cortical layer (Figure 1B).
Smad3 depletion leads to fewer dopaminergic neurons in
the rostral SN
Because TGF-b1 can provide both pro-survival or death
signals to cells, we determined whether Smad3 deficiency
altered the number of dopaminergic neurons in the VM.
We analyzed the nigrostriatal system in 2- to 3 -month-
old Smad3 knock-out male mice in the basal state. These
mice develop to term and live to adulthood, surviving to
2 to 4 months of age. They exhibited subtle phenotypic
abnormalities, such as osteopenia, while 1/3 of the mice
developed malformations of the forelimbs and rib cage
[19], curvature of the spine (kyphosis) and resting tremor
(data not shown). The brains of Smad3
-/- mice exhibited
ag r o s s l yn o r m a lm o r p h o l o g y .I n d e e d ,w h e nw eu s e d
unbiased stereological methods to quantify the number
of dopaminergic neurons along the rostro-caudal axis of
the A9, A10 and A8 areas of Smad3
-/- and Smad3
+/+
mice, the numbers were similar in the null and wild-type
mice genotypes in both the A10 and A8 dopaminergic
areas (Figure 2A, Additional file 1A). However, Smad3
depletion led to a 34.8% decrease in the number of TH-ir
neurons in the rostral SN (P = 0.004, Figure 2B-C). We
could not detect stronger Smad3 expression in the rostral
portion of the SN (data not shown), suggesting a func-
tional spatial differentiation of this signalling molecule.
Although the number of dopaminergic neurons
decreased in the rostral portion of SN in Smad3 null
mice, TH protein levels in the VM were similar to those
found in control mice (P = 0.566, data not shown). We
assessed apoptosis in the SN of these mice using TUNEL
assay (to measure nuclear DNA fragmentation) and mor-
phological criteria (shrunken, smooth-appearing nuclei
that have lost the granularity, associated with nuclear
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Page 2 of 22Figure 1 Smad3 is expressed in dopaminergic neurons of the SN. (A) Expression of TGFb ligands, receptors and Smad3 signalling molecules
in the VM and ST of adult mice. RT-PCR from three adult mice are shown under basal conditions for the expression of TGF-b1, -b2, and -b3
ligands, ALK1, ALK2, ALK5 type I receptors, TbR-II type II receptor, Smad2 and Smad3 receptor activated Smads, the common Smad4, and the
inhibitory Smad7. Every PCR reaction was performed using 1 μl of the cDNA pool, except for TGF-b3 and ALK1 in the VM where 1, 2 and 3 μl
were tested. (B) Coronal sections were double immunostained for TH and Smad3. SN dopaminergic neurons express Smad3 in the cytoplasm,
although some neurons have Smad3 in the nucleus (arrows). Quantitative estimate of the values representing colocalized pixels in the dual-color
image shows the co-localization of both signals in the SN (Pearson correlation coefficient = 0.62). Confocal images of TH/Smad3 double-labelling
in the ST and the motor cortex (Cx-M) suggested region co-localization, but not at the cellular level. Scale bar 50 μm.
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Page 3 of 22chromatin condensation) [20]. We could not detect a
clear increase in apoptotic cells in the SN of Smad3
-/-
mice (Additional file 1B). Considering that the criteria
used to measure apoptosis last for a few hours (both
nuclear condensation and fragmentation), it seemed pos-
sible that neuronal death might be greater at older ages.
Unfortunately, these knockout mice did not survive
beyond 4 months of age and thus, an analysis of older
animals was not possible.
TGF-b3, but not TGF-b1, has been shown to be
required for the survival of dopaminergic neurons in
perinatal stages [15]. In order to discriminate between a
developmental defect and a degenerative process in the
SN of adult Smad3 null mice, we quantified the number
of rostral TH-ir neurons in day 0 of postnatal age (P0).
Similar number of dopaminergic neurons was found in
Smad3 null mice and control mice (Figure 2E), indicating
a postnatal degenerative process in Smad3 deficiency
(Figure 2C).
We evaluated whether Smad3 was necessary to maintain
dopaminergic striatal innervation from nigral dopaminer-
gic neurons, and whether the rostral deficit in DA neurons
might have a positional effect in the ST. We quantified the
optical density of TH-ir fibres along the rostro-caudal axis,
as well as in the dorsal and ventral ST. No changes were
observed between the wild type and mutant mice (Addi-
tional file 2A). Furthermore, there was no alteration in
striatal TH protein content (Additional file 2B). Dopamine
transporter (DAT) immunoreactivity was also assayed in
the ST of these mice. Smad3 deficiency resulted in a not-
statistically significant trend to decrease DAT expression
in the rostral ST (P = 0.095, Additional file 3A-C). This
trend is observed in the rostral ST, similar to the rostral
decrease on TH-ir neurons in the SN, although in a wider
Figure 2 Degeneration of dopaminergic neurons in the rostral SN of Smad3 null mice. (A) Quantification of TH-ir neurons was determined
using unbiased stereological methods in the midbrain A9, A10 and A8 dopaminergic areas (which include the SN, ventral tegmental area and
retrorubral field, respectively). No clear differences were observed between mice when the entire pool of TH-ir cells was counted in these areas.
The stereological counting method had a CE < 0.07 for each mouse. (B-C) Representation of the SN (A9) along the rostro-caudal axis showed
that Smad3
-/- mutant mice had fewer TH-ir neurons than Smad3
+/+ in the initial rostral 500 μm of the SN (*P < 0.05, **P < 0.01, Mann-Whitney
Rank Sum test). Similar values were detected between mice in the middle and caudal regions. Unpaired t-test, n = 5 for Smad3
+/+ and n = 6 for
Smad3
-/- mice. (D) Unbiased stereological quantification of Nissl(+) neurons in the ST of Smad3
+/+ and Smad3
-/- mice (Unpaired t-test, n = 4
mice per genotype). CE ≤ 0.05. (E) Quantification of TH-ir neurons in the rostral portion of the midbrain at perinatal stage (P0). Similar values
were found between Smad3
+/+ and Smad3
-/- mice, indicating no developmental defect, but a postnatal degenerative process in Smad3
deficiency (Student’s t-test, n = 3-4 per genotype). (F) Confocal microscopic images of Smad3/TH double-labelled neurons in the SN of Smad3
+/+
and Smad3
-/- mice. In control tissues, some neurons show Smad3 translocated to the nucleus (arrow). Smad3 null mutant mice have no
expression of the protein.
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loss in the ST. Unbiased stereological quantification of
Nissl(+) neurons showed that Smad3 deficiency did not
alter the number of striatal neurons (Figure 2D), suggest-
ing that the pro-survival effect of Smad3 may be specific
to the dopaminergic neurons of the SN in the mesostriatal
system. Together, the loss of TH-ir neurons in the SN and
the trend to decrease the presynaptic DA marker in the
ST (DAT) seems to suggest an early loss of dopaminergic
neurons in Smad3 null mice.
Smad3 null mice have less GFAP expressing astrocytes
The effect of the absence of Smad3 on astrocytes -expres-
sing glial fibrillary acidic protein (GFAP)- and microglia
-detected by CD11b-ir, which is upregulated on activated
microglia- was explored in the nigrostriatal system of
these mice. Microglial cells were not clearly altered in
Smad3 deficient mice (data not shown). However, the
number of astrocytes in the SN apparently decreased even
when assessed at low magnification (Figure 3A-B). Quanti-
fication of the ventral, middle and lateral SN (Additional
f i l e4 A - C )s h o w e dt h a tS m a d 3
-/- mice had 38.0% less
GFAP-ir cells than Smad3
+/+ mice (P = 0.004) (Figure 3G).
Indeed, in the ST, Smad3 deficiency induces a 32.1%
decrease in GFAP-ir cells in the matrix compartment
of the dorsal zone (the TH-fibre rich region; P = 0.014,
Figure 3H). To further explore this effect we examined the
levels of GFAP protein expressed in the VM and ST of
these animals. The GFAP protein content is decreased in
null mutant mice by 63.9% in the VM (P < 0.001) and by
55.3% in the ST (P = 0.004, Figure 3I). Moreover, while
morphological changes were not apparent in astrocytes
from the SN (Figure 3A-D), some atrophy in the arboriza-
tion of astrocytes, with thin branching, is exhibited in the
ST of Smad3 null mice (Figure 3E-F).
We searched for Smad3 immunoreactivity in GFAP(+)
astrocytes within the SN of wild-type mice. Co-localization
of Smad3 and GFAP was evident (Figure 3J), suggesting
that Smad3 could provide a survival signalling for astro-
cytes. Astrocytes are the main element of brain homeo-
static system and loss of astrocytes in Smad3 deficient
mice may decrease trophic and metabolic support to sur-
rounding neurons.
Striatal DA catabolism and oxidative stress increase when
Smad3 is depleted
We further tested whether striatal DA levels is altered.
Similar levels of DA were found in Smad3 null mice and
control mice, although a strong increase in DA catabo-
lism was detected in the former (Figure 4A). Thus, in
Smad3 deficient mice the striatal levels of DOPAC,
homovanillic acid (HVA), and 3-methoxy-tyramine (3-
MT) increased by 94.5% (P = 0.001), 59.8% (P < 0.001),
and 28.1% (P = 0.007), respectively. The increase in DA
oxidation was primarily mediated by MAO since the
DOPAC/DA ratio augmented 98.8% (P = 0.004, Figure
4B). Catechol-O-methyl transferase (COMT) activity,
quantified by 3-MT/DA ratio, did not increase signifi-
cantly (33.9%, P = 0.101). This Smad3-dependent effect
might be relatively specific for DA because striatal sero-
tonin was not clearly altered (Additional file 5). It is
known that the oxidation of DA to DOPAC is accompa-
nied by the stoichiometric reduction of oxygen to H2O2
[21]. Hence, the 2-fold increment in MAO-mediated DA
oxidation must increase striatal oxidative stress. The nor-
mal detoxification pathway for H2O2 is the glutathione
system, supplied by the mitochondria. We measured
striatal glutathione content in its reduced (GSH) and oxi-
dized (GSSG) forms (Figure 4C). Smad3
-/- mice had
35.9% more striatal GSH than Smad3
+/+ mice (P =
0.043). We could speculate on a compensatory mechan-
ism by anti-oxidant GSH defence in order to detoxify
excess of H2O2 produced by increased DA turnover in
Smad3 deficiency.
MAO-B increases in the ventral midbrain of Smad3
null mice
The increment in DA catabolism without a modification
in DA levels may be related to alterations in different
mechanisms, such as increased MAO levels or decreased
vesicular DA storage. Once re-uptaked from the presynap-
tic terminals, DA can either be repackaged into synaptic
vesicles by the vesicular monoamine transporter (VMAT-
2) or catabolyzed by MAO. We analyzed the striatal
VMAT-2 content and we observed that Smad3 deficiency
did not alter their protein levels (Figure 5B). However,
Smad3 ablation increased the MAO-B content in the VM
by 38.9% (P = 0.010, Figure 5A). In the ST, the change in
MAO-mediated DA catabolism (Figure 4B) does not seem
to correlate with protein content alteration, suggesting
changes in MAO-B activity for the 2-fold increment in
DOPAC/DA ratio. On the other hand, dopaminergic
somatodendrites in SN can synthesize, store and release
DA. The increment in MAO-B protein levels could parti-
cipate in the catabolism of DA in somatodendrites. More-
over, the SN contains high levels of MAO-B positive
astrocytes and its elevation in mouse brain results in par-
kinsonism [22]. Moreover, MAO-B activity levels have
been found to be doubled in the SN of PD [23].
Smad3 deficiency decreases the phosphorylation of the
Smad2 linker region
Smad3-deficiency may induce an increment in Smad2 sig-
nalling in an attempt to compensate for the TGF-b signal-
ling deficit. In order to evaluate this possibility we
measured the phosphorylation of Smad2 at two different
locations (Figure 6A). The carboxyl terminus is phos-
phorylated by TGF-b activated type I receptors, while the
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Page 5 of 22Figure 3 Smad3
-/- mice have fewer nigrostriatal astrocytes. In the SN the number of GFAP-ir astrocytes decreased in Smad3 deficiency (A-B,
G). Illustrations depict non-activated astrocytes as verified by the labelling of thin, elongated processes in the wild-type (C) and null (D) mice. In
the ST, atrophic astrocytes could be detected in Smad3
-/- null mice (F, arrow) when compared to Smad3
+/+ mice (E). (H) Number of GFAP-ir
cells in the striatal matrix and striosomes. The figure represents the GFAP-ir cells per mm
2 in one striatal hemisphere. (I) The GFAP protein
content is decreased in both the VM and ST of Smad3 null mice (Student’s t-test, n = 4-6 per genotype) (J) Confocal images of Smad3 and
GFAP double-labelled cells in the SN of wild-type mice showed co-localization of Smad3 in astrocytes. *P < 0.05, **P < 0.01, ***P < 0.001
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signals such as MAPKs, CaMKII or CDKs [24]. In immu-
noblots, phosphorylation of the Smad2 carboxy-terminal
was not altered in the VM or the ST of Smad3
-/- mice
(Figure 6B). However, the phosphorylation of the linker
region decreased by 48.4% in the VM (P = 0.028) and
20.8% in the ST (P = 0.037, Figure 6C). Decreased phos-
phorylation in the linker region might be indicative of
weaker modulatory intracellular signalling. However, there
is no indication of any significant compensatory up-regula-
tion in activity at the Smad2 carboxy-terminal.
Cross-talk between Smad3 and Erk1/2, but not JNK or
p38 MAPKs
The decreased activation in the linker region of Smad2
may imply a deficiency in MAPK signalling. Extensive
cross-talk between TGF-b signalling and JNK, Erk or
p38 occurs at different levels to promote or inhibit
Figure 4 Smad3 ablation induces an increase in MAO-mediated DA catabolism in the ST. (A) Loss of Smad3 leads to increased catabolism
of striatal DA, with no alterations in total neurotransmitter content. (B) The catabolism of DA in Smad3 deficient mice is primarily MAO-mediated
(DOPAC/DA ratio) as compared to COMT (3-MT/DA). (C) The striatal GSH content of Smad3
-/- mice is also higher than in Smad3
+/+ mice. (*P <
0.05, **P < 0.01, ***P < 0.001, Student’s t-test, n = 6 per genotype)
Tapia-González et al. Molecular Neurodegeneration 2011, 6:72
http://www.molecularneurodegeneration.com/content/6/1/72
Page 7 of 22apoptosis [11]. Furthermore, JNK-cJun activation has
been implicated in the pathogenesis of PD [25]. In order
to determine whether an interaction between Smad3
and MAPKs exists in the nigrostriatal system, we evalu-
ated the endogenous levels of phosphorylated JNK, p38
and Erk1/2 in Smad3 null mice. The phosphorylation of
JNK and p38 in the VM and ST was similar in Smad3
+/+ and Smad3
-/- mice (Additional file 6A-B), as were
the striatal levels of p-Erk1/2 (P = 0.537, for p-ERK2
p42,
Figure 7A). However, Smad3 ablation led to a significant
decrease in p-Erk1
p44 (38.7%, P = 0.032) and p-Erk2
p42
(20.3%, P = 0.038) in the VM (Figure 7A). Immunohis-
tochemistry for p-Erk1/2 showed a granular distribution
in dopaminergic neurons of the SN. Interestingly, a gen-
eral decrease in the number of these cytoplasmic gran-
ules labelled for p-Erk1/2 was detected in Smad3 null
mice (Figure 7B, data not shown). In summary, two
MAPKs implicated in the induction of cell death, such
as JNK and p38, are not regulated by Smad3 under
basal conditions. However, activation of the pro-survival
MAPK Erk1/2 was diminished in nigral dopaminergic
neurons after Smad3 depletion. These results suggest
that Smad3 activates Erk1/2 in dopaminergic neurons
and that Smad3 deficiency may decrease the trophic
support provided by Erk1/2 signalling.
Increased expression and aggregated a-synuclein in
Smad3
-/- mice
The molecular events detected in Smad3
-/- mice were
highly suggestive of early signs of parkinsonism. One of
the pathological hallmarks in PD is abnormal a-synuclein
aggregation and inclusion body formation. When we
examined the expression of a-synuclein in immunoblots
of the VM and ST of these mice, similar protein levels
were found in the VM (Figure 8A). However, Smad3 defi-
ciency increased the expression of a-synuclein in the ST
by 20% (P = 0.028). To further assess this response, we
performed immunohistochemistry in the ST and we
quantified the optical density of a-synuclein fibres in this
area (Figure 9H-J). Smad3
-/- mice displayed a 16% trend
to increase (P = 0.024) in the density of a-synuclein
along the rostrocaudal ST when compared to wild-type
mice (Figure 8B).
Biochemically, a-synuclein inclusions are resistant to
extraction with non-ionic detergents like Triton X-100.
Conversely, extraction with ionic detergents such as SDS
disrupts a-synuclein aggregation into monomers and
SDS-stable oligomers [26]. We detected aggregated forms
of a-synuclein by immunohistochemistry (see below,
Figures 9K, N, R and 10). A range of aggregates is
observed, from strongly- to mildly-detected, in male
Smad3 deficient mice at this age (2-3 months old). We
further characterized these aggregates by sequentially
extracting tissue from the VM, ST and M1 motor cortex
in detergents of increasing strength [27]. To verify the
specificity of the signal detected, a-synuclein null mice
were used as a control. In Western blots, a specific 12-14
k D ab a n dt h a tc o r r e s p o n d e dt oa-synuclein monomers
was detected, which was not detected in the a-synu-
clein
-/- mice. Indeed, most a-synuclein monomers were
extracted in the Triton X-100 and SDS soluble fractions
( F i g u r e8 C ) .I ts h o u l db en o t e dt h a tt h ea n t i b o d yr e a c t s
with non-specific bands in the a-synuclein
-/- mice that
differ from those observed in mice of the Smad3 colony.
Interestingly, soluble oligomers of 45-50 kDa could be
detected in the Triton X-100 phase of VM from Smad3
null mice and a faint 22-24 KD band was detected in
Smad3
-/- mice, mainly present in the primary motor cor-
tex, suggestive of soluble dimers. High molecular weight
SDS-insoluble aggregates were detected in the VM and
motor cortex of Smad3 null mice (Figure 8D). Quantifi-
cation of insoluble monomeric a-synuclein highlighted a
2.1-fold induction (p = 0.010) in the motor cortex in
Smad3 null mice (Figure 8E). Interestingly, there was a
clear increment of SDS-insoluble monomers and oligo-
mers in the spinal cord of Smad3 null mice, primarily in
the lumbar region (Figure 8F), suggesting the appearance
of inclusions in these regions.
We further characterized a-synuclein by immunohisto-
chemistry along the rostrocaudal brain axis, and we
Figure 5 Smad3 deficiency leads to increased MAO-B levels in the ventral midbrain. (A) Smad3
-/- mice had higher MAO-B levels in the VM
than Smad3
+/+ mice. (B) VMAT-2 protein contents are not altered in Smad3
-/- mice. Bars represent values normalized to b-tubulin from 6 mice
per group, each measured two to three times. **P < 0.01, Student’s t- test.
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of different telencephalic, mesencephalic and romboence-
phalic regions (Figure 9 A-Q). Indeed, the specificity of
this staining was verified in a-synuclein null mice (data
not shown). To further study the distribution of a-synu-
clein, we compared old mice (21 month-old wild-type and
19 month-old heterozygous for Smad3), as well as young
mice (3 month-old wild-type and Smad3 null mice). There
was no difference in the distribution of a-synuclein
between young Smad3 heterozygous and wild-type mice.
However, a-synuclein aggregates where detected in young
Smad3 null mice and in old Smad3 heterozygous mice,
Figure 6 Decreased Smad2 phosphorylation in Smad3 null mice. (A) The MH1 and MH2 domains in Smad2, conserved in other Smads, are
connected by a less-conserved linker region. TGF-b and MAPKs signalling induces phosphorylation of certain sites in Smad2. (B) The level of
activated Smad2 (carboxy-terminal phosphorylation) is not modified by Smad3 ablation. (C) However, in Smad3 null mice the linker region is less
phosphorylated, suggesting a decrease in an intracellular regulatory signal of Smad2 (*P < 0.05, Student’s t-test, n = 6 per genotype, each
measured two to three times).
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Page 9 of 22suggesting a gene dosage and age dependent progressive
effect. Interestingly a-synuclein aggregates were detected
in fibres of the primary and secondary motor cortex, cin-
gulate cortex, ST and corpus callosum (Figure 9A-D, H-
K). Moreover, perinuclear a-synuclein aggregates were
evident in the cell bodies of the SN, paralemniscal nucleus,
and pontine nuclei of old heterozygous and primarily
young Smad3 null mice (Figure 9L-N). Furthermore,
Smad3 deficient mice manifested a clear increase in stain-
ing, associated with an irregular morphology and neurite
thickness, in fibres from the internal capsule, corpus callo-
sum, lateral lemniscus, cerebral peduncle and spinal
trigeminal tract (Figure 9A-E, O-P). At the level of the 2
nd
and 3
rd cerebellar lobe (Figure 9E), and of the anterior
white matter of the spinal cord (Figure 9G, Q) positively
labelled cells resembling glia were detected (star shape
appearance, arborizing processes, and a mean diameter of
4.3 ± 0.5 μm) [28], together with positive fibres. In the
lateral lemniscus, a broad dentritic arbor was detected
(Figure 9P).
In order to verify that the a-synuclein aggregates
detected in the SN of Smad3 deficient mice are degener-
ating dopaminergic neurons, we performed confocal
imaging of a-synuclein and TH double-labelled neurons
Figure 7 Decreased Erk1/2 signalling in dopaminergic neurons of Smad3
-/- mutants. (A) Analysis of the phosphorylation state of Erk1/2
MAPK in the VM and ST of Smad3 null mice identifies a specific decrease in Erk1/2 activation in the VM (*P < 0.05, Student’s t-test, n = 6 per
genotype, each measured two to three times). (B) Immunolabelling for p-Erk1/2 defines granular cytoplasmic structures in dopaminergic neurons
that are fewer when Smad3 is depleted.
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Page 10 of 22(Figure 9R). Co-localization of TH and a-synuclein is
observed in the cytoplasm of dopaminergic neurons of
the SN, both in control and Smad3 deficient mice.
Furthermore, a-synuclein aggregates present in Smad3
deficiency co-localize with TH in this brain area, further
suggesting a relationship between the dopaminergic
alterations detected in Smad3 deficiency and the pre-
sence of a-synuclein aggregates.
Figure 8 Increased expression and aggregated a-synuclein in Smad3
-/- mice. (A) Immunoblots of ST and VM tissue show that Smad3
deficiency increases the striatal a-synuclein content (*P < 0.05, Student’s t-test with n = 6 mice per genotype, measured in triplicate). (B) Further
evaluation of a-synuclein expression by immunohistochemistry along the rostro-caudal axis of the ST. Twenty brain sections per mice were
counted from Smad3
+/+ (n = 5) and Smad3
-/- (n = 6). Figure indicates values for the rostral 1000 μm. O.D. quantification shows an increase in
the ST of Smad3 null mice (*P < 0.05, Student’s t-test). (C-F) Several nervous system regions from Smad3 wild-type and null mice were subjected
to graded detergent extraction (Triton-soluble, SDS-soluble, and SDS-insoluble fractions) and analyzed in Western blots. The molecular weight
markers on the left indicate the protein size in kilodaltons (**P < 0.01, Student t-test, n = 3 for Smad3
+/+, n = 5 for Smad3
-/-, n = 2 for a-
synuclein
-/- mice).
Tapia-González et al. Molecular Neurodegeneration 2011, 6:72
http://www.molecularneurodegeneration.com/content/6/1/72
Page 11 of 22Figure 9 Aggregation of a-synuclein in specific brain areas. (A-G) Rostrocaudal distribution of a-synuclein in Smad3 wild-tupe and deficient
mice. Red points represent positive a-synuclein staining in wild-type and null mutant. Blue asterisks illustrate cellular and neuritic aggregates
present in old heterozygous and young Smad3 null mice. (H-Q) Photomicrography showing a-synuclein positive structures. (H-J) ST striatum, (K)
M1 primary motor cortes, cc corpus callosum in Smad3
-/-, (L-N) SN substantia nigra, (O) cp cerebral peduncle, (P) ll lateral lemniscus, and (Q) fa,
anterior funiculus of the spinal cord. The double arrows show positive fibres detected in Smad3 deficient mice, asterisks point to synaptic
terminals with a punctuate morphology, and the arrowheads indicate perykarial inclusions. (R) Confocal microscopic images of TH/a-synuclein/
Dapi triple labelling in the SN of Smad3
+/+ and Smad3
-/- mice. In control tissues, a-synuclein is present in the cytoplasm of dopaminergic
neurons. The aggregates observed in Smad3 deficiency are double-labelled for both molecules (arrow). The window is further magnified to get a
better appraisal of the accumulation of a-synuclein in a TH(+) neuron.
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Page 12 of 22a-Synuclein deposits in Smad3 deficiency accumulates
ubiquitin and P
S129-a-synuclein
Phosphorylation of serine 129 is a widespread a-synuclein
post-translational modification within LB and inclusions
isolated from human brain with PD, Multiple System
Atrophy (MSA), dementia with Lewy bodies (DLB) and
other synucleinopathies. Furthermore, the majority of a-
synuclein found in LB are mono- to tri-ubiquitinated [29].
In order to evaluate whether these post-translational mod-
ifications of a-synuclein are present in the aggregated
forms detected in Smad3 deficiency, we performed dou-
ble-immunostaining using anti-P
S129-a-synuclein and
anti-ubiquitin antibodies in the SN of Smad3 deficient
mice (Figure 10A). In the wild-type mice ubiquitin could
be found in the cytoplasm of neurons and P
S129-a-synu-
clein in neurites and dendrites. However, in Smad3 defi-
cient mice we could detect aggregates with both proteins.
Interestingly, in mice with less clear deposits of a-synu-
clein the distribution of ubiquitin and P
S129-a-synuclein
revealed a core of ubiquitin, surrounded by a halo of
P
S129-a-synuclein (Figure 10A, arrows). It is of note that
accumulation of ubiquitin could also be observed within
these halos. On the other hand, mice with more clear
inclusions detected by anti-a-synuclein antibody show
stronger accumulation of ubiquitin, surrounded by a
strong rim of P
S129-a-synuclein. These ubiquitin/P
S129-a-
synuclein double-labelled aggregates were found isolated
(arrowhead) or in small groups (double arrowhead). Dou-
ble-labelling with a-synuclein antibody shows co-localiza-
tion with ubiquitin within the core of these deposits
(Figure 10B).
This core/rim cellular distribution may resemble those
observed in human patients with LB diseases [29] and
further suggest a key role of Smad3 signalling in the
homeostasis of a-synuclein.
The presence of a-synuclein inclusions, with post-
translational modifications observed in the human LB, in
specific brain areas of Smad3 deficient mice suggests a
neuropathological status in these mice, which together
with the strong DA catabolism, the loss of dopaminergic
neurons and decreased trophic and astroglial support
detected, may resemble early symptoms of parkinsonism
in these mice.
Discussion
The strong catabolism of striatal DA associated with the
increment of a-synuclein expression and inclusions in
selected brain areas, which are phosphorylated at Ser
129
and ubiquinated, might represent an interesting model
of parkinsonism and/or a-synucleinopathies. Moreover,
Smad3 knockout mice have fewer astrocytes in the SN,
less nigral dopaminergic neurons, diminished trophic
support mediated by Erk1/2 signalling, and increased
oxidative stress (Figure 11).
In the mouse brain, TGF-b ligands, receptors and Smad
signalling molecules are expressed in the VM and ST.
Indeed, the dopaminergic neurons of the SN express
Smad3, suggesting that TGF-b ligands can act directly on
these neurons. The loss of dopaminergic neurons in
Smad3
-/- mice from the rostral SN might result from an
alteration during the perinatal stage due to TGF-b3 signal-
ling [15]. However, adult Smad3
-/- mice do not manifest
the overt DA neuron loss observed in TGF-b3 null mice,
resembling the effect of TGF-b1 deficiency. Moreover, the
decrease in the number of TH-ir neurons in the rostral
SN is not observed at P0, suggesting no developmental
defect but a postnatal degenerative process. An alternative
pathway could account for TGF-b3 during perinatal stage,
such as those involving Smad2. Moreover, mRNA TGF-b3
is not present in the adult VM, and several ligands should
be considered to activate Smad3 in the adulthood, such as
TGF-b1, -b2, Inhibin, Activin, or GDF1. Our results sug-
gest that Smad3 deficiency may be particularly important
for adult midbrain pathology since we detect a progressive
loss of dopaminergic neurons and a progressive onset of
a-synuclein aggregation, with a late onset in the heterozy-
gous mice (19-20 months), when compared with the early
onset in the null mice (2-3 months). These neurons may
be compromised by decreased Erk1/2 trophic support and
increased striatal oxidative stress. It has already been
established that Erk1/2 can phosphorylate Smad3 in the
linker region, and Erk1/2 and Smad3 converge on the pro-
moters of TGF-b targeted genes [30]. On the other hand,
TGF-b can activate Ras-Erk1/2 signalling in a Smad-inde-
pendent manner [31]. However, our studies show another
level of interaction, because Erk1/2 activity is dependent
on Smad3 in dopaminergic neurons. Erk1/2 signalling has
been implicated in numerous biological processes such as
cell survival and neurite outgrowth. Erk1/2 can be com-
partmentalized to different subcellular structures, such as
the nucleus, Golgi, endosomes or plasma membrane.
Notably, phosphorylated Erk1/2 has been detected in PD
within SN neurons, and with a granular distribution in
mitochondria and autophagosomes [32].
Primary cultures of astrocytes derived from human and
mouse brain are known to secrete TGFb molecules and to
express the Smad3 signalling pathway. In vitro studies have
shown the role of TGFb/Smad3 in the secretion of TGF-
b2 for the increment of extracellular matrix proteins in
human optic nerve head astrocytes, in the context of glau-
coma [33], the regulation of iNOS production by TGF-b1/
Smad3 after inflammation [34], or the induction of
Jagged1-Notck signalling for oligodendrocyte progenitor
proliferation and differentiation [35]. Interestingly, TGF-b1
arrests astrocyte proliferation in G1 phase, through
the induction of p15
INK4B [36]. Hence, we could expect
an increase in the number of astrocytes in Smad3 defi-
ciency. However, we observe a decrease in the number of
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Page 13 of 22Figure 10 a-synuclein deposits in Smad3 deficiency are ubiquitinated and S129 phosphorylated. (A) Confocal images of aggregates
double-labelled with ubiquitin and P
S129-a-synuclein in the ventral midbrain of Smad3 deficient mice. Different morphologies could be
detected, from a clear core of ubiquitin surrounded by a halo of P
S129-a-synuclein (arrows), to strong accumulation of ubiquitin and P
S129-a-
synuclein in isolated (arrowhead) or groups (double arrowhead) of deposits. (B) a-synuclein staining co-localize with ubiquitin within the core of
the aggregates.
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Page 14 of 22astrocytes in the SN and striatal matrix of these mice. Pre-
vious studies from Wang and colleagues [36], using astro-
cyte cultures derived from Smad3 null mice, have shown
that Smad3 is necessary, but not sufficient, for the induc-
tion of p15
INK4B and growth inhibition, suggesting an indir-
ect mechanism for Smad3 on astrocyte proliferation. On
the other hand, TGF-b1 is normally expressed at low levels
in the basal state of mice and this mechanism on astrocyte
proliferation could be only active after brain injury [3-10].
Our results suggest a protective role of Smad3 signalling
on astrocytes in the basal state. Astrocytes provide homeo-
static control of the extracellular environment of neurons.
The number of astrocytes decreases in the SN and dorsal
striatal matrix of Smad3 null mice and hence, DA neurons
and their striatal terminals may have fewer surrounding
astroglial cells to detoxify oxygen free radicals and to
secrete neurotrophic factors. Furthermore, astrocytes in
the ST may have atrophy in their arborization, with thin
and elongated processes, suggesting a phenotypic alteration
in the remaining astrocytes. This limited astroglial environ-
ment might make neurons more vulnerable to oxidative
stress and provide less trophic support to DA neurons.
Indeed, loss of astrocytes and dystrophic astrocytes has
been associated to several dementias, which correlates with
the severity of the disease. In this sense, it is suggested that
atrophy of astroglial cells may develop before gross neuro-
degenerative alterations [37].
Although Smad3 does not regulate striatal TH protein
content or DA levels, DA turnover is doubled in Smad3
knockout mice, primarily due to MAO-dependent cata-
bolism. This neurotransmitter degradation might be spe-
cific for DA, because striatal serotonin metabolism is not
altered. DA turnover is elevated in the brain of PD
patients and in experimental models after partial loss of
dopaminergic neurons. Partial neuronal degeneration
leads to over-activity of the remaining dopaminergic neu-
rons, inducing increased DA release and turnover in
order to maintain both normal DA levels in the synaptic
cleft and dopaminergic input to postsynaptic targets.
However, this mechanism of compensation may contri-
bute to the progress of the disease by promoting endo-
genous oxidative stress [38]. Increased MAO-catalyzed
H2O2 production can also damage mitochondria through
the oxidation of GSH [21]. A similar situation is observed
after Smad3 ablation. Indeed, the increase in DA turn-
over in the ST of Smad3 deficient mice increments the
production of H2O2 and oxidative stress, as suggested by
the increment in GSH levels, in an attempt to detoxify
cells. Moreover, the 35.9% increment in GSH levels does
not seem to be sufficient to detoxify the 2-fold induction
in H2O2 and over time, the GSH system could be over-
whelmed, leading to extensive oxidative damage.
The increment in DA catabolism without any modifi-
cation in DA levels may be related to alterations in
Figure 11 Illustration of the working model of pathogenic mechanisms of Smad3 deficient mice, in the cell body (A) and synaptic
terminal (B) of mesostriatal dopaminergic neurons.
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Page 15 of 22different processes, such as increased MAO activity or
decreased vesicular DA storage. An alteration in DA
reuptake by synaptic vesicles through the vesicular
transporter VMAT-2 would leave the DA in the cytosol,
exposed to degradation by MAO. However, we have not
detected any variation in VMAT-2 striatal protein con-
tent. On the other hand, the increased catabolism of DA
appears to be due to MAO-B activity, and its increment
could degrade extracellular DA producing less activation
in post-synaptic targets. Finally, Smad3 might directly
regulate MAO-B at the transcriptional level although
this remains to be clarified. The role of MAO-B in the
pathogenesis of PD is currently being examined and
clinical studies indicate that its inhibition may slow the
progression of the disease. Indeed, MAO-B inhibitors
are used clinically with L-DOPA treatment with inter-
esting protective effects [39].
One of the major pathological events in PD, and of a-
synucleinopathies, is the abnormal aggregation of a-synu-
clein in specific brain areas. Indeed, increased endogenous
a-synuclein level due to gene dosage promotes the disease
in humans [40]. In this sense, the increased expression of
a-synuclein in the ST of Smad3 null mice is suggestive of a
progressive pathological state. Furthermore, the increase in
soluble and insoluble monomers/oligomers, the presence
of detergent-insoluble oligomers of a-synuclein in the VM,
motor cortex and spinal cord, as well as the aggregations
in the perikarya and neurites in the nigrostriatal system,
are similar to the properties of a-synuclein inclusions in
human disease [26,41,42]. Accordingly, the accumulation
of ubiquitin and P
S129-a-synuclein within these deposits,
and their cellular distribution as a core/halo, further sug-
gest post-translational modifications similar to that present
in LB of human a-synucleinopathies [29]. These results
suggest that a-synuclein may become cross-linked, prob-
ably as a consequence of increased DA catabolism and oxi-
dative stress. Indeed, 3,4-dihydroxyphenylacetaldehyde
(DOPAL), a MAO intermediate metabolite of DA, can
induce toxic aggregation of a-synuclein [43]. Alternatively,
we could speculate that Smad3 might directly regulate the
transcription of the a-synuclein gene. It is already known
that a-synuclein can modulate DA metabolism by regulat-
ing TH, and by directly binding to DA, VMAT-2 and DAT
[44]. In this manner, the increased catabolism in DA
observed in Smad3 null mice could be due to the prior
increase in a-synuclein expression.
These findings suggest a selective pathology in specific
brain regions by Smad3 deficiency. Moreover, late onset of
a-synucleinopathies in the heterozygous mice when com-
pared with the early onset in the Smad3 null mice suggests
that aggregates accumulate in a progressive and gene
dosage dependent manner with age. Indeed, the specific
a-synuclein aggregation in the nigrostriatal system, and in
the cingulate and motor cortices, is also detected in PD
[44-46]. However, alterations (increased staining, irregular
morphology, and neurite thickness) in other regions of the
brain of Smad3 null mice (pontine nuclei, cerebellar white
matter, cerebral peduncle, diencephalic nuclei and internal
capsule), as well as the presence of glial cells in the cere-
bellum and spinal cord may correlate with other synuclei-
nopathies such as Multiple System Atrophy [47]. Though,
Smad3 deficiency manifests phenotypic symptoms, such as
curvature of the spine (kyphosis) and resting tremor that
is characteristic of parkinsonism. The mechanism involved
in the formation of inclusions from wild-type human a-
synuclein is still unclear, although the evidence that a
TGFb-Smad3 deficiency may induce their formation high-
lights a new interesting mechanism to be explored.
Mice lacking the a-synuclein, parkin, DJ-1 or PINK1
expression have deregulated striatal DA metabolism,
release or reuptake, without any alteration in the number
of dopaminergic neurons in the SN. While in six indepen-
dent parkin deficient mice generated there are no clear
nigrostriatal deficits or common phenotypes, increased
extracellular DA, decreased DAT, increased GSH levels
and differences in the catabolism of DA have been
described [48-50]. Neither the number of dopaminergic
neurons nor DA striatal levels and turnover are altered in
DJ-1 or PINK knock-out mice. However, in these mice the
evoked DA overflow diminishes due to increased DA
uptake [51] or to the decreased quantal release of DA [52],
respectively. a-Synuclein knock-out mice have less striatal
DA content, enhanced activity-dependent DA release and
reduced synaptic vesicle reserve pools [53,54], which may
be due to a uninhibited DA vesicular release [55]. All
these mutant mice illustrate that impaired presynaptic DA
metabolism, release or reuptake may be common in PD,
suggesting that the strong catabolism of DA detected in
Smad3 null mice may be an early mechanism for the
degeneration of dopaminergic neurons.
Conclusions
The phenotype observed in Smad3 knock-out mice
shows that TGFb-Smad3 signalling regulates the catabo-
lism of DA, promote the survival of dopaminergic neu-
rons and astrocytes and participate in the metabolism of
a-synuclein in specific brain areas. Smad3 deficiency
may correlate with early signs of parkinsonism, and
alterations in TGFb-Smad3 signalling may contribute to
the pathogenesis of parkinsonism. Indeed, Smad3 null
mice could be useful as a model to explore the relation-
ship between inflammation, trophic support, DA turn-
over and a-synuclein pathologies. Moreover, this model
may be valuable to screen for novel therapeutic strate-
gies that inhibit or reverse a-synuclein aggregate forma-
tion and that regulate DA catabolism.
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Immunohistochemistry
Six male 8 to 14-weeks old mice were used per group. The
animals were deeply anesthetized with Avertin and per-
fused via the ascending aorta with 0.9% saline followed by
fresh, ice-cold 4% paraformaldehyde in 0.1M phosphate-
buffered saline (PBS), pH 7.4. The animals brains were
removed, postfixed at 4°C for 2 h in the same fixative, and
cryoprotected in 12% sucrose-PBS solution for 48 h at
4°C. The brains were snap-frozen in liquid dry ice-cooled
isopentane, and 20 μm coronal cryostat sections were cut
and stored at -80°C until use. For TH/Smad3 co-immuno-
labelling, amplification of the Smad3 signal was obtained
using the TSA™ Plus Cyanine 3 System (PerkinElmer,
Massachusetts) with some modifications to reduce back-
ground. Tissues were permeabilized for 1 h with PBS plus
1% Triton X-100. Endogenous peroxidase activity was
quenched with 0.3% H2O2 in methanol, and non-specific
staining was blocked with 10% normal serum/0.3% Triton
X-100 in PBS plus 10 μg/ml avidin. Brain sections were
incubated at 4°C overnight in blocking solution plus
50 μg/ml biotin with the mouse anti-TH (1:1000, Chemi-
con, California) and rabbit anti-Smad3 (1:100, Abcam,
Cambridge. UK) primary antibodies. The sections were
rinsed in PBS and then incubated with anti-mouse Alexa
Fluor 488 (1:150, Molecular Probes, Invitrogen) for 1 h at
room temperature. After rinsing in PBS, the sections were
incubated with biotinylated anti-rabbit IgG for 1 h, rinsed
in PBS, and exposed to an avidin-biotin peroxidase com-
plex for 1 h (Vectastain, VectorLabs, California). After
washing in PBS, Cy3-Tyr was diluted 1:200 in the kit
amplification solution, and it was added to the sections for
10 min at room temperature. After rinsing in PBS, the
brain tissue was mounted in ProLong Gold (Invitrogen)
and for quantitative statistical analysis, the images were
processed using Image-Pro Plus 4.0 software (MediaCy-
bernetics, Bethesda, MD) and its Pearson’s correlation
application.
To identify apoptosis in the SN, the ApopTag Peroxi-
dase In Situ Apoptosis Detection kit (Chemicon) was used
according to the manufacturer’s instructions. Co-labelling
of TUNEL(+) cells (visualized with diaminobenzidine as a
substrate), and TH(+) neurons (visualized by fluorescence)
was performed Briefly, antigen retrieval by boiling slices in
10 mM citrate buffer pH 6.0 for 10 min was followed by
inhibition of endogenous peroxidase activity with 3%
H2O2. Sections were incubated in ApopTag equilibration
buffer for 15 min at room temperature, and then in work-
ing strength TdT enzyme buffer during 1 h at 37°C. After
washing, sections were exposed to the anti-digoxigenin
peroxidase conjugate overnight at 4°C, and the peroxidase
activity was visualized with diaminobenzidine as a sub-
strate. TH labelling was performed in the same sections,
using mouse anti-TH (1:300) and anti-mouse Alexa Fluor
488 as previously described. TUNEL positive controls
were conducted by treating sections with DNase I (1 μg/
ml) to induce DNA strand breakage and as negative con-
trols TdT was excluded from the assay.
Standard chromogenic immunohistochemistry was per-
formed for TH, DAT, GFAP, and a-synuclein [17] using
rabbit anti-TH (1:3000, Institut J. Boy, France), rat anti-
DAT (1:500, Chemicon), rabbit anti-GFAP (1:2750,
Abcam), and mouse anti-a-synuclein antibodies (1:1000,
BD Transduction Lab, California). The a-synuclein stain-
ing was further developed using the Vector MOM™ per-
oxidase kit (Vector Labs). Measurement of the cell body
(maximum diameter) of a-synuclein positive cells in the
white matter of spinal cord was performed directly on the
screen of a monitor coupled to the microscope using the
Scion Image Beta 4.02 software program (Scion Corp.,
Maryland, USA). Data were expressed as mean ± s.d. of
n = 50 cells.
Double immunofluorescence was performed using
mouse anti-GFAP (D1:1500, Chemicon), mouse anti-ubi-
quitin (D1:100, Chemicon), rabbit anti-P
S129-a-synuclein
(D1:50, Abcam), mouse anti-a-synuclein (D1:150), rabbit
anti-ubiquitin (D1:200, Abcam), and rabbit anti-TH
(D1:100). Vector MOM™ kit (Vector Labs) was used for
the antibodies generated in mouse. The fluorescent-
labelled secondary antibodies used were Alexa Fluor 488
and Alexa Fluor 568 (D1:250, Invitrogen) from different
species. Furthermore, antigen retrieval was used for ubi-
quitine/P
S129-a-synuclein, and a-synuclein/TH double
labelling. For each case, sections were immunolabelled in
triplicate and images were acquired and analyzed by con-
focal microscopy (Nikkon C1 plus ECLIPSE Ti-e micro-
scope and a 60X Plan Apo VC OIL objective with NA 1.4).
An estimation of the number of astrocytes in the SN
and ST using GFAP-ir was performed with the observer
blind to the experimental treatment. The ST was deli-
neated with the 2X objective, dividing the dorsal and ven-
tral tiers (as described in [56]). The number of GFAP-ir
cells was performed using the objective at 60X, counting
every GFAP-ir cell within the delineated region. GFAP-ir
cells were counted in a 1:6 series of sections (20 μmp e r
section, 120 μm apart each), from Bregma 1.54 mm to
Bregma -0.46 [57]. Moreover, GFAP-ir cells were classi-
fied as located in the striatal striosome or matrix. Only
the GFAP-ir cells with a continuous labelling in ≥ 3 rami-
fications and excluding those present in the border were
counted. Positive labelling near vessels was excluded due
to the difficulty to distinguish unique cells. Total number
of GFAP-ir cells was estimated considering the section
sampling fraction (1:6). In the SN we analyzed ten brain
sections per mouse. For each section, three rectangular
regions were delineated (ventral R1, middle R2, and
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Page 17 of 22lateral R3, Additional file 4A), with the objective at 2X.
For estimation of the number of GFAP-ir cells an objec-
tive 20X was used and the counting regions were main-
tained equidistant from each other along the SN per
section. Data is expressed as GFAP-ir cells per mm
2.
The optical density (O.D.) of TH, DAT and a-synuclein
staining in the ST was assessed with the Image Pro Plus
4.0 image analysis software. Briefly, sections of different
groups were stained simultaneously, and every reaction,
including DAB chromogenic development, was precisely
timed to ensure comparability. Images of coronal sections
of the whole ST were visualized using a 2X objective and
captured under identical lighting conditions. The measure-
ment system was calibrated with a reference slide and inci-
dent/black light, and a total of 21 coronal 1:6 serial
sections (20 μm per section, 120 μm apart each) per
mouse were analyzed. The ST was delineated and O.D.
values were used to express staining intensities.
Stereological cell counting
TH-ir neurons were counted in a 1:5 series of sections (20
μm per section, 100 μm apart each) from Smad3
-/- and
Smad3
+/+ mice using the optical fractionator method, an
unbiased cell counting method that is not affected by
either the volume of reference or the size of the counted
elements [58]. Neurons were counted twice, with the
observer blind to the experimental group. The stereology
system consists of an Olympus BX51 microscope fitted
with a XYZ motorized computer stage (Prior ProScan,
Rockland, MA), a digital microcator (Heidenhain,
Schaumburg, IL), and the CAST-2 Stereological software
(Olympus, Tokyo). Neurons were counted twice, with the
observer blind to the experimental treatment, each section
was observed at low magnification (objectives 10X and
2X) and the dopaminergic areas A9, A10 and A8 were
delineated according to the anatomical landmarks defined
in German et al. [59]. The sampling was performed
according to unbiased stereological principles using a
100 × 100 μm step length and a counting frame. Dopami-
nergic neurons were counted under an oil immersion
objective (60X, NA = 1.25, Olympus) with the counting
unit established as the nucleolus of TH-ir cells. The total
positive cell number (N) was estimated using the equation:
N=s u m Q
- ×1 / s s f×1 / a s f×1 / t s f ,w h e r es u m Q
- is the
total number of neurons counted with the fractionator, ssf
is the section sampling fraction, asf is the sampling frac-
tion area, and tsf is the sampling fraction thickness. The
reliability of the sampling scheme was confirmed by the
calculation of the coefficient of error (CE), which was
<0.07. For striatal Nissl-stained sections, four mice per
genotype were analyzed. Five coronal sections per mice
were counted, starting from Bregma 1.42 mm [57], using
the same unbiased optical fractionator method previously
described, with the following details: 1:6 series of sections
(20 μm per section, 120 μm apart each), sampling with
300 × 300 μm step length, and results with a CE ≤ 0.05.
Data is expressed as Nissl(+) cells per mm
2.
RNA extraction and RT-PCR
T h eS Ta n dt h eV Mw e r ei s o l a t e df r o m3s i x - m o n t h - o l d
control C57Bl/6J mice. Freshly dissected tissue was imme-
diately submerged in RNAlater™ solution (Ambion,
Austin, TX) to prevent RNA degradation and total RNA
was isolated using a RiboPure™ Kit (Ambion) according
to the manufacturer’s instruction, and stored at -80°C
until use. Equal amounts of RNA and cDNA were used
for RT and PCR, respectively, in order to provide similar
conditions on each reaction. cDNA was prepared from
500 ng of total RNA with oligo(dT)12-18 primers (Invitro-
gen, California) using SuperScript™ III Reverse Transcrip-
tase (Invitrogen) in a total volume of 20 μl. The cDNA
products were stored at -20°C until they were used as tem-
plates for PCR. The oligonucleotides used to detect the
expression of TGF-b1, TGF-b2, TGFb-3, ALK1, ALK2,
ALK5, TbR-II, Smad2, Smad3, Smad4 and Smad7 are
described in Machida et al. [60]. Thirty-five cycles of PCR
were performed, using a mix with 1 μl of cDNA product,
1.5 mM MgCl2, 0.25 mM dNTPs, 0.3 μM of each primer,
and 2 U of Taq DNA Polymerase (Applied Biosystems,
California) in a total volume of 20 μl. The whole PCR
reaction was loaded onto a 1.5% agarose gel.
Mouse line and genotyping
Smad3 knock-out mice [19] have a 129 × C57Bl/6 genetic
background. Heterozygous and homozygous Smad3 defi-
cient mice in a C57Bl/6 background are not fertile (data
not shown). To establish the colony, we selected breeders
with a 50% contribution of each strain by analyzing 60
microsatellites covering 19 autosomal chromosomes (data
not shown). For experiments both wild-type and knockout
mice were obtained by intercross breeding of heterozygous
mice, and they were characterized by PCR analysis of
DNA from tail biopsies, with primers: com, 5’-CTCCA-
GAGTTAAAAGCGAAGTTCG-3’;w t ,5 ’-AAAATGCTG-
CACGGAAGCCAGGTC-3’; and neo, 5’-ATTTGTCACG
TCCTGCACGACG-3’. The wt and mutant PCR products
are 489 bp and 347 bp, respectively. For all analyses, 2-3
month old mice were used as the mortality rate increases
in older knock-out mice. Procedures with mice were in
accordance with EU and Spanish legislation on animal
welfare.
Monoamine and metabolite analysis
Six animals per group were anesthetized with isofluor-
ane and their striata were rapidly dissected, frozen in
dry ice and stored at -80°C until analysis. For catechol
analysis, the tissue was homogenized by sonication
(VibraCell, level 2 for 30 seconds) in 8 volumes (w/v) of
Tapia-González et al. Molecular Neurodegeneration 2011, 6:72
http://www.molecularneurodegeneration.com/content/6/1/72
Page 18 of 22ice-cold 0.4 N perchloric acid (PCA) with 0.5 mM
Na2S2O5 and 2% EDTA, and then centrifuged for 20
min at 11,000 g and 4°C. The supernatant was then
used to determine the monoamines and their metabo-
lites (20 μl) as well as for glutathione, and the pellet was
used for protein extraction. DA and its metabolites
DOPAC, HVA, and 3-MT, and serotonin (5-HT) and its
metabolite 5-hydroxy-indole-acetic acid (5-HIAA), were
measured according to Mena et al., [61]. Briefly, the
supernatants were analyzed on a Nucleosil 5C18 column
using electrochemical detection (ESA Coulochem,
Chelmsford, MA). The mobile phase consisted of a
0.1 M citrate/acetate buffer pH 3.9 with 10% methanol,
1M EDTA and 1.2 heptane sulfonic acid. The detector
voltage conditions were D1 (+0.05), D2 (-0.39) and the
guard cell (+0.40).
Glutathione measurements
Total glutathione levels were measured by the method of
Tietze [62]. The striatal homogenate (40 μl) used for
High-performance liquid chromatography (HPLC) analysis
(in 0.4N PCA) was neutralized with 4 volumes of phos-
phate buffer (0.2 M NaH2PO4,0 . 2MN a 2HPO4,0 . 5M
EDTA, pH 7.5) and the resulting preparation (50 μl) was
diluted 1/10 with PBS and mixed with 0.6 mM DTNB,
0.2 mM NADPH and 1U GSH reductase. The reaction
was monitored in a P96 automatic microtiter reader at
412 nm for 6 min. Oxidized glutathione (GSSG) was mea-
sured by the method of Griffith [63], whereby the neutra-
lized striatal homogenate (120 μl) was mixed with 2-
vinylpyridine (1.2 μL) at 22-24°C for 1 h and the reaction
was carried out as described above. Reduced glutathione
(GSH) was obtained by subtracting oxidized glutathione
from total glutathione levels.
Protein extraction and immunoblotting
The pellet obtained from the striatal homogenate (in PCA)
was neutralized with 1/9 (w/v) lysis buffer (0.75% Na2CO3,
2% SDS, 10 μg/ml leupeptin, 2 μg/ml aprotinin, 1 mM
PMSF, 2 mM o-vanadate), sonicated and centrifuged for
30 min at 11,000 g and 4°C. The supernatant was used for
protein quantification by the BCA assay (Pierce, Rockford,
IL) and 10-20 μg of each sample was resolved by 12%
SDS-PAGE for immunoblotting (Bio-Rad, California). Pro-
teins were transferred to PVDF membranes (Hybond-P,
Amersham, UK) and detected using a chemiluminescence
detection system. The primary antibodies used were raised
against TH (1:6000, Institut Jacques Boy, France), p-JNK
(1:5000, Cell Signaling, Danvers, MA), p-Erk1/2 (1:3000,
Cell Signaling), p-P38 (1:3000, Cell Signaling), p-Smad2-
Cter (1:4000, Cell Signaling), p-Smad2-Linker (1:4000, Cell
Signaling), b-tubulin (1:10000, Cell Signaling), MAO-B
(1:5000, Santa Cruz), VMAT-2 (1:3000, Santa Cruz), a-
synuclein (1:6000, BD Transduction Laboratories). Briefly,
membranes were blocked for 1 h with 0.4% ECL Advance
blocking reagent (Amersham) in Tris-buffered saline
(TBS) with 0.1% Tween-20 (TTBS), and incubated with
the primary antibody at 4°C overnight. After washing, the
membranes they were incubated for 2 h with anti-rabbit
IgG-HRP (1:15000, Amersham) or anti-goat IgG-HRP
(1:15000, Santa Cruz) in blocking buffer. After rinsing in
TTBS, the reaction was visualized using the ECL Advance
Western Blotting Detection Kit (Amersham). Images were
captured using VersaDoc Imaging System (Model 4000,
Bio-Rad), and the band densities were quantified with
ImageQuant TL software (Amersham). Band intensities
within the linear range were normalized to the signal
obtained in the same lane with an anti-b tubulin antibody
to control for variability in protein loading. We measured
b-tubulin protein levels in Smad3
+/+ and Smad3
-/- mice (6
mice per group, measured in 6 replicates). No difference
in the expression of b-Tub was detected between mice
(P = 0.264, data not shown), validating the utility of this
protein as a loading control. Each protein was analyzed in
6 mice per group and experiments were performed in
duplicate or triplicate.
Sequential detergent extraction of a-synuclein
The motor cortex, ST, VM, cervical and lumbar spinal
cord from Smad3
+/+ and Smad3
-/- mice (3-4 months old)
were dissected out, weighed and homogenized by sonica-
tion in 3 ml/g of buffer A (10 mM Tris-HCl [pH 7.6],
0.15 M NaCl, 1% Triton X-100, and protease inhibitors).
The a-synuclein null mice were used as a control of the
signal (a kind gift from Dr. Isabel Fariñas). Sequential
detergent extraction was performed as described by Ihara,
et al. [27]. Briefly, the supernatant recovered after centrifu-
gation at 15,000 × g at 4°C for 30 min was considered as
the “Triton soluble” extract. The pellet was sonicated and
re-extracted with 1 ml/g of buffer B (10 mM Tris-HCl
[pH 8.0], 0.15 M NaCl, 1% Triton X-100, 0.5 sodium deox-
ycholate, and 0.1% SDS), and it was fractionated by centri-
fugation at 15,000 × g at 4°C for 30 min. This supernatant
w a sc o n s i d e r e da st h e“SDS-soluble fraction”.T h ep e l l e t
was again dissolved by sonication and boiled in buffer C
(3% SDS and 5% b-mercaptoethanol, 1 ml/g pellet), and
the lysate was considered as the “SDS-insoluble fraction”
(Ihara, et al., 2007). Protein quantification of each fraction
was performed by the BCA (bicinchoninic acid) protein
assay, and 50-75 μg of each sample was resolved by 12%
SDS-PAGE as described previously.
Statistical analyses
SigmaStat software (SSPS, Chicago, IL) was used for all
analyses and all values were expressed as the means ± s.e.
m. The normal distribution of the data was assessed to use
parametric or non-parametric tests. Differences between
the means were analyzed with the unpaired t-test (for
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rank sum test (as non-parametric test). In all analyses, the
null hypothesis was rejected at the 0.05 level. (*), (**), and
(***) indicates P ≤ 0.05, P ≤ 0.01, and P ≤ 0.001,
respectively.
Additional material
Additional file 1: Normal gross morphology of the SN in Smad3
deficiency. (A) Coronal brain section of a Smad3
+/+ and Smad3
-/- mouse
showing dopaminergic neurons in the SN and the ventral tegmental
area stained with an antibody against TH. The mesencephalic gross
morphology is not altered in Smad3 deficiency (B) Quantification of
TUNEL (+) cells in the SN showed no clear increase on apoptosis in
Smad3 deficient mice, (3.60 ± 0.81 in Smad3
+/+, 4.71 ± 1.57 in Smad3
-/-
mice, P = 0.590, unpaired t-test, n = 6-7 per group). Representative
images of the apoptotic cells counted. The criteria to count apoptotic
cells was both morphological (cells with nuclear chromatin
condensation) and molecular (nuclear DNA fragmentation shown by
TUNEL). Only cells with the DNA of the entire nucleus both fragmented
and condensed were counted (stage 2 of apoptotic degradation) [20].
These apoptotic cells lacked immunoreactivity for TH (not shown).
Additional file 2: No alteration in striatal TH content in Smad3 null
mice. (A) TH-ir quantification of Smad3
+/+ and Smad3
-/- mice by O.D. in
the dorsal and ventral tiers of the ST. The entire ST along the rostro-
caudal axis was counted from Smad3
+/+ (n = 5) and Smad3
-/- (n = 6)
mice. (B) Immunoblot analysis of striatal TH showed no difference
between mice. Arbitrary units refers to the TH content normalized to b-
tubulin. Bars represent values from duplicate measures of 6 mice per
group.
Additional file 3: Trend to decrease striatal DAT expression in
Smad3
-/- mice. DAT expression in the rostro-caudal and dorso-ventral
axis of the striatum of Smad3
-/- mice. Quantification of DAT
immunoreactivity (A) in the ST of Smad3
+/+ and Smad3
-/- mice by optical
density (O.D.) in the dorsal (B) and ventral tiers (C) of the ST. For rostro-
caudal analyses twenty brain sections per mice were counted from n = 5
mice per genotype. Bar figures indicate segregated values for the rostral
(initial 1000 μm) and caudal portions of the striatum.
Additional file 4: GFAP(+)astrocytes in the SN in Smad3 deficiency.
GFAP-ir astrocytes in the SN of wild-type (A) and Smad3 null mice (B). (C)
Estimation of the number of GFAP-ir cells in three areas of the SN -
ventral (R1), middle (R2) and lateral (R3)- in serial slices (from bregma
-3.08 to bregma -3.8). Unpaired t-test, four brain sections per mice from
n = 4 mice per genotype.
Additional file 5: Smad3 deficiency does not alter striatal serotonin
levels (5-HT) or its catabolite (HIAA). Student’s t-test, n = 6 for Smad3
+/+ and Smad3
-/- mice.
Additional file 6: Analysis of the phosphorylation state of JNK and
p38 in Smad3 deficiency. (n = 6 per genotype, each measured two to
three times).
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